EICHORCondition: Diabetes Mellitus, Type 2 · Sponsor: Novo Nordisk A/S
This study compares 2 medicines for type 2 diabetes: semaglutide (new medicine) and a dummy medicine (placebo). Semaglutide will be tested to see how well it works compared to the dummy medicine. The study will also test if semaglutide is safe in children and teenagers. Participants will either get semaglutide or the dummy medicine - which one is decided by chance. Participants will take 1 tablet of the study medicine every morning on an empty stomach. They have to wait 30 minutes before they eat, drink or take any other medication by mouth. The study will last for about 1 year and 3 months (66 weeks). Participants will have 12 clinic visits and 8 phone calls with the study doctor. At all 12 clinic visits, participants will have blood samples taken. Participants will also be asked some questions.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Informed consent from parent(s) or legally acceptable representative (LAR) and child assent from the subject obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial. * Male or female, aged 10 to below 18 years at the day of randomisation * HbA1c 6.5%-11.0% (47-97 mmol/mol) (both inclusive) * Diagnosed with type 2 diabetes mellitus according to the American Diabetes Association criteria and treated with: * stable metformin dose (stable metformin dose is defined as at least 1000 mg daily or the maximum tolerated dose for 56 days or longer prior to screening) or * stable metformin dose and a stable dose of basal insulin (stable dose of basal insulin is defined as basal insulin treatment equal to or more than 30 days prior to screening, compared to the dose at screening, dose adjustments of ± 25% are allowed) or * stable dose of basal insulin Exclusion Criteria: * Diagnosis of type 1 diabetes * Maturity onset diabetes of the young (MODY) * Positive insulinoma associated-protein 2 (IA-2) antibodies or anti-glutamic acid decarboxylase (anti-GAD) antibodies.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| UAB Ped Endo Children's Hosp | Birmingham, Alabama, United States | — |
| Children's Hospital Los Angeles - Endocrinology | Los Angeles, California, United States | — |
| Yale School Of Medicine | New Haven, Connecticut, United States | — |
| Nemours Chld Clnc Jacksonville | Jacksonville, Florida, United States | — |
| Nemours Children's Health | Pensacola, Florida, United States | — |
| University of South Florida Diabetes Center | Tampa, Florida, United States | — |
| Children's Healthcare Atlanta | Atlanta, Georgia, United States | — |
| Columbus Research Foundation | Columbus, Georgia, United States | — |
| Indiana Uni School of Med-Ped | Indianapolis, Indiana, United States | — |
| University Of Louisville Research Foundation | Louisville, Kentucky, United States | — |
| Pennington Biomed Res Ctr | Baton Rouge, Louisiana, United States | — |
| Barry J. Reiner, MD LLC | Baltimore, Maryland, United States | — |
+ 85 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04596631